APAC’s antimicrobial resistance-related costs to reach $904b by 2050

Investment in AMR solutions could generate US$10 to 15b in annual healthcare savings.

In Asia Pacific, antimicrobial resistance-related costs are projected to reach up to $904b (US$700b) by 2050, accounting for up to 1% of the region’s gross domestic product according to a report by The Centre for Impact Investing and Practices and the World Economic Forum.

In 2021, AMR caused 4.7 million deaths annually and is estimated to become the leading cause of death by 2050, claiming more than 8 million lives and surpassing cancer.

Beyond health, it threatens global food systems by reducing global livestock production and polluting waterways.

However, the report noted that timely investment in AMR solutions could generate $12.9b (US$10b) to $19.4b (US$15b) in annual healthcare savings and cut annual socio-economic costs by up to US$40b in the region.

($1=US$0.77)

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia